Connexin 43 and Sonic Hedgehog Pathway Interplay in Glioblastoma Cell Proliferation and Migration.
GBM
GLI1
connexin
gap junction
smoothened
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
12 Aug 2021
12 Aug 2021
Historique:
received:
06
07
2021
revised:
06
08
2021
accepted:
06
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Glioblastoma (GBM) represents the most common primary brain tumor within the adult population. Current therapeutic options are still limited by high rate of recurrences and signalling axes that promote GBM aggressiveness. The contribution of gap junctions (GJs) to tumor growth and progression has been proven by experimental evidence. Concomitantly, tumor microenvironment has received increasing interest as a critical process in dysregulation and homeostatic escape, finding a close link between molecular mechanisms involved in connexin 43 (CX43)-based intercellular communication and tumorigenesis. Moreover, evidence has come to suggest a crucial role of sonic hedgehog (SHH) signalling pathway in GBM proliferation, cell fate and differentiation. Herein, we used two human GBM cell lines, modulating SHH signalling and CX43-based intercellular communication in in vitro models using proliferation and migration assays. Our evidence suggests that modulation of the SHH effector smoothened (SMO), by using a known agonist (i.e., purmorphamine) and a known antagonist (i.e., cyclopamine), affects the CX43 expression levels and therefore the related functions. Moreover, SMO activation also increased cell proliferation and migration. Importantly, inhibition of CX43 channels was able to prevent SMO-induced effects. SHH pathway and CX43 interplay acts inducing tumorigenic program and supporting cell migration, likely representing druggable targets to develop new therapeutic strategies for GBM.
Identifiants
pubmed: 34439999
pii: biology10080767
doi: 10.3390/biology10080767
pmc: PMC8389699
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : PhD program in Biotechnology
ID : Biometec - University of Catania
Organisme : PON AIM R&I 2014-2020
ID : E66C18001240007
Organisme : Italian Ministero dell'Istruzione, dell'Università e della Ricerca, PRIN 2017
ID : 2017XKWWK9_004
Références
Transl Res. 2021 Sep;235:144-167
pubmed: 33582245
CA Cancer J Clin. 2020 Jul;70(4):299-312
pubmed: 32478924
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Oncoimmunology. 2019 Oct 21;8(12):e1678921
pubmed: 31741780
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
Cell. 2019 Aug 8;178(4):835-849.e21
pubmed: 31327527
Genome Biol. 2021 Jan 14;22(1):33
pubmed: 33446260
Pol J Pathol. 2021;72(1):1-10
pubmed: 34060283
Int J Cancer. 2012 Jul 15;131(2):E33-44
pubmed: 22072503
Mol Carcinog. 2016 May;55(5):537-51
pubmed: 25728352
J Neurooncol. 2011 Sep;104(3):697-704
pubmed: 21380601
Oncogene. 2019 Jun;38(23):4429-4451
pubmed: 30814684
Int J Mol Sci. 2020 Aug 06;21(16):
pubmed: 32781585
Mol Cell Biochem. 2019 Apr;454(1-2):11-23
pubmed: 30251117
Curr Biol. 2007 Jan 23;17(2):165-72
pubmed: 17196391
J Dev Biol. 2016 Dec 10;4(4):
pubmed: 29615598
Cancers (Basel). 2016 Feb 15;8(2):
pubmed: 26891329
Cancer Res. 2003 Sep 15;63(18):5821-8
pubmed: 14522905
Int J Mol Sci. 2020 May 30;21(11):
pubmed: 32486205
Genes Dev. 2002 Nov 1;16(21):2743-8
pubmed: 12414725
FEBS Lett. 2014 Apr 17;588(8):1186-92
pubmed: 24434539
Inflamm Res. 2020 Sep;69(9):841-850
pubmed: 32533221
Stem Cells. 2007 Oct;25(10):2524-33
pubmed: 17628016
Mol Med Rep. 2015 Nov;12(5):6702-10
pubmed: 26299938
Biochim Biophys Acta. 2012 Aug;1818(8):2058-67
pubmed: 22063721
Int J Mol Sci. 2020 Jan 23;21(3):
pubmed: 31979397
Mol Cancer Res. 2011 Sep;9(9):1165-74
pubmed: 21775419
Gene. 2000 Jun 27;251(2):123-30
pubmed: 10876089
Front Cell Neurosci. 2018 Aug 03;12:235
pubmed: 30123112
Nature. 2004 Nov 18;432(7015):396-401
pubmed: 15549107
Wiley Interdiscip Rev Dev Biol. 2020 Jan;9(1):e361
pubmed: 31468728
Pharmacol Res. 2021 Sep;171:105780
pubmed: 34302977
Biochim Biophys Acta. 2012 Dec;1826(2):338-49
pubmed: 22677165
Respir Res. 2005 Sep 13;6:103
pubmed: 16159396
Int J Mol Sci. 2020 Jul 23;21(15):
pubmed: 32717889
Hum Mol Genet. 2009 Aug 1;18(15):2899-911
pubmed: 19439426
World Neurosurg. 2018 Aug;116:505-517
pubmed: 30049045
Oncotarget. 2018 Jun 5;9(43):27000-27015
pubmed: 29930746
J Cell Physiol. 2020 Apr;235(4):3798-3814
pubmed: 31613002
Nat Rev Neurosci. 2002 Jan;3(1):24-33
pubmed: 11823802
Mol Pain. 2016 Sep 02;12:
pubmed: 27590071
Nat Protoc. 2006;1(5):2315-9
pubmed: 17406473
Front Physiol. 2017 Dec 18;8:1060
pubmed: 29326598
Biol Open. 2019 Mar 26;8(3):
pubmed: 30837226
Oncotarget. 2017 Jun 27;8(26):42495-42509
pubmed: 28477008
Mol Neurobiol. 2019 Nov;56(11):7338-7354
pubmed: 31030416
Curr Opin Pharmacol. 2018 Aug;41:79-88
pubmed: 29803991
Cell Commun Signal. 2018 Mar 20;16(1):11
pubmed: 29558958
EBioMedicine. 2021 Feb;64:103205
pubmed: 33493796
Cell Commun Signal. 2017 Oct 2;15(1):37
pubmed: 28969644
Dev Growth Differ. 2002 Dec;44(6):537-47
pubmed: 12492512
Int J Mol Sci. 2020 Nov 23;21(22):
pubmed: 33238452
Int J Mol Sci. 2019 Mar 26;20(6):
pubmed: 30917493
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 28096261
Aging (Albany NY). 2017 Apr;9(4):1233-1247
pubmed: 28446712
Int J Mol Sci. 2020 Mar 12;21(6):
pubmed: 32178267
Int J Mol Sci. 2019 Apr 23;20(8):
pubmed: 31018557
Semin Cancer Biol. 2005 Apr;15(2):75-83
pubmed: 15652452
Nat Commun. 2018 Dec 18;9(1):5377
pubmed: 30560870
Histopathology. 2011 Jun;58(7):1037-47
pubmed: 21707705
Front Neurosci. 2019 Mar 19;13:143
pubmed: 30941001
Cancers (Basel). 2020 Oct 04;12(10):
pubmed: 33020459
J Cell Sci. 2006 Feb 1;119(Pt 3):532-41
pubmed: 16418219
Cell Tissue Res. 2005 Jun;320(3):409-15
pubmed: 15846511
Nat Chem Biol. 2006 Jan;2(1):29-30
pubmed: 16408088
J Cell Mol Med. 2017 Oct;21(10):2563-2572
pubmed: 28488330
Life Sci. 2020 Sep 15;257:118027
pubmed: 32622951